"The therapies that are currently available are working to remove peptides that are likely the result of a bigger issue we can target before those peptides can start forming plaques. We're demonstrating that by targeting the brain's metabolism, we can not only slow, but reverse the progression of this disease."
"Their findings suggest that IDO1 may also be relevant in diseases with other types of pathology, such as Parkinson's disease and dementia as well as the broad spectrum of progressive neurodegenerative disorders known as tauopathies ..."
MedicalXpress article:
medicalxpress.com/news/2024...
Research paper: Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies.
PD needs paradigm shift: eg, Alzheimer's, HSV1, P. gingivalis, amyloid-beta and tau are antimicrobial peptides.
Encouraging results from the phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in PD
Will Tasigna, an FDA-approved cancer drug, be the first drug to revere symptoms of Parkinson's and dementia? 
